Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio

Boston Pharmaceuticals has posted early evidence that its ex-Novartis candidate works in nonalcoholic steatohepatitis (NASH). But with Akero Therapeutics and 89bio taking rival drugs to the cusp of phase 3, it's unclear whether the biotech can differentiate BOS-580 from more advanced candidates.